Latest News

  • 12 Apr 2021
    Oncurious NV Reports Encouraging Data from Phase 1 Dose Escalation Study of TB-403 in Paediatric Subjects with Relapsed or Refractory Medulloblastoma Presented at the American Association for Cancer Research 2021 Annual Meeting
  • 9 Apr 2021
    ONCURIOUS Presenting Clinical and Preclinical Data at Upcoming American Association for Cancer Research (AACR) 2021 Annual Meeting
  • 24 Feb 2021
    Oncurious Announces Publication in Journal for Immunotherapy of Cancer highlighting the efficacy and safety of targeting CCR8 for the depletion of tumor-promoting Tumor Infiltrating Tregs in combination with anti-PD-1 therapy
  • 22 Oct 2020
    ONCURIOUS NV Announces First Preclinical Proof of Concept in Proprietary CCR8 Treg Program
  • 11 Jun 2019
    ONCURIOUS NV Receives Project Grant from VLAIO to Progress its Pipeline of Next Generation Cancer Immunotherapies